Slamon DJ, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465-72 Slamon DJ, et al. Overal...
1. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanc...
Slamon DJ, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465-72 Slamon DJ, et al. Overall Survival with Ribociclib plus Fulvestrant in...
1.Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet ...
2. WHAT TYPES OF PERSONAL DATA DO WE COLLECT ABOUT YOU? The information we collect and process about you depends on how you use our Services—as a Business User, End Customer, Prospective Customer, or Visitor. We may collect, use, store and transfer different kinds of Personal Data about ...
P364364. Why study Portuguese 5 reasons to get started 02:09 P365365. 2 Hours of Daily Portuguese Conversations - Portuguese Practice for ALL Lea 2:02:21 P366366. Learn Portuguese 247 with PortuguesePod101 TV 03:38 P367367. How to Talk About Your Hobbies In Portuguese 31:00 P368368....
Legal entity responsible for the study: Pfizer Inc Funding: Pfizer Inc Disclosure: V. Diéras: Consulting and advisory role: Genentech, Lilly, Pfizer, AbbVie, Novartis Pharma KK, Roche-Peru. Speakers bureau: Pfizer, Novartis Pharma KK, Roche-Peru. N. Harbeck: Honoraria: Lilly, Novartis, Pfiz...
[1] Finn RS, Crown JP, Lang I, et al. Thecyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozoleversus letrozole alone as first-line treatment of oestrogen receptor-positive,HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2study. Lancet Onc...
参考文献: Natasha Leighl,et al.Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: The phase Ib PALOMA study . 2024 ELCC:6MO. 责任编辑|KOP
Thecyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozoleversus letrozole alone as first-line treatment of oestrogen receptor-positive,HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2study. Lancet Oncol. 2015. 16(1): 25-35. [2] /record/...